Phase 4 N=33 Clinical and Cost Effectiveness of ACE Inhibitor, Ramipril, in Intermittent Claudicants
Intermittent Claudicants
Primary: Maximum Walking Distance (MWD). — 137; 143 Metres
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=210 Spanish Intervention for Caregivers of Veterans With Stroke
Depression
Primary: Change in Caregiver Depression at 9 Weeks — 15.0; 10.2 score on a scale — p=0.001
N/A N=38 Modern Urodynamics System Efficacy (MUSE) Study
Urologic Diseases · Urodynamics
Primary: Percentage of Participants With Insertion Success — 32 Participants
Phase 2 N=28 Pharmacologic Augmentation of Targeted Cognitive Training in Schizophrenia
Schizophrenia · Schizoaffective Disorder
Primary: Primary Clinical Outcome PANSS Total Score (PANSSt) — 65.4; 55.6; 67.1; 49.8 score on a scale — p=0.28
Phase 3 N=304 Pre-Exposure Prophylaxis for Transgender Women in the US and South America
HIV Prevention
Primary: PrEP Uptake — 16.2; 11.4 days
N/A N=105 FoodRx for Obesity Treatment
Obesity · Food Insecurity
Primary: Percent Change in Total Body Weight at 24 Weeks (BWL+VOUCHER and BWL+HOME vs BWL-Alone) — -2.7; -3.0 Percent initial weight loss
N/A N=124 Decreasing the Temporal Window in Individuals With Alcohol Use Disorder
Alcohol Use Disorder
Primary: Delay Discounting (DD) Rates — -4.69; -5.15; -4.92; -5.58 ln(K-value) — p=.60
Phase 1 N=24 Safety and Virologic Effect of a Human Monoclonal Antibody (VRC01) Administered Intravenously to Adults During Early Acute HIV Infection
HIV Infections
Primary: Number of Participants With Grade 3 or Greater mAb-related Reactogenicity and mAb-related Adverse Events (AEs) — 0; 0; 1 Participants
Phase 3 N=61 Cognitive-Behavioral and Pharmacologic (LDX) Treatment of Binge-Eating Disorder and Obesity: Maintenance Treatment
Binge-Eating Disorder · Obesity
Primary: Binge-Eating Relapse — 3; 5 Participants
Phase 2 N=44 Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors
Advanced Solid Tumor
Primary: Number of Participants With Adverse Events and Deaths — 2; 2; 3; 3 Participants
Phase 2 N=48 A Study to Evaluate Cortisol Reserve in Response to Adrenocorticotropic Hormone (ACTH) Stimulation Test Following Baxdrostat Treatment Compared to Placebo in Participants With Uncontrolled Hypertension
Uncontrolled Hypertension
Primary: Number of Participants With Serum Total Cortisol Level Before and After Adrenocorticotropic Hormone (ACTH) Stimulation Test — 0; 0; 26; 15 Participants
N/A N=100 High Protein, Core Muscle Rehab, Muscular Electrostimulation in Prolonged Mechanical Ventilation
Prolonged Mechanical Ventilation · Protein Deficiency
Primary: Weaning Rate — 3; 20; 22; 26 Participants
N/A N=38 Acute Neural and Immune Effects of Alcohol in People Living With HIV Infection
HIV-1-infection · Alcohol Drinking
Primary: Plasma Biomarker of Microbial Translocation — 58.562; 99.285; 77.232; 97.343 pg/ml — p=.343
N/A N=300 Management of Nausea and Vomiting Chemotherapy-induced in Normandy
Cancer · Nausea · Vomiting
Primary: Number of Participants With Acute Nausea and Vomiting — 101 Participants
N/A N=22 Combining VNS With PT Interventions for Individuals With PD
Parkinson Disease
Primary: Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III — 31.00; 36.70; 25.1; 26.8 Scores on a scale